Technical Analysis for SVRA - Savara, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Historical SVRA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Stochastic Sell Signal | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.92% | |
| Bollinger Band Squeeze | Range Contraction | 3.92% | |
| Weak + Overbought | Other | 3.92% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2020
- Sector: Healthcare
- Industry: Biotechnology
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Medicine Pharmaceutical Cystic Fibrosis Heart Failure Heart Diseases Treatment Of Heart Failure Staphylococcus Aureus Total Synthesis
Medicine Pharmaceutical Cystic Fibrosis Heart Failure Heart Diseases Treatment Of Heart Failure Staphylococcus Aureus Total Synthesis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.48 |
| 52 Week Low | 0.69 |
| Average Volume | 344,514 |
| 200-Day Moving Average | 2.20 |
| 50-Day Moving Average | 2.32 |
| 20-Day Moving Average | 2.02 |
| 10-Day Moving Average | 2.03 |
| Average True Range | 0.14 |
| ADX | 13.93 |
| +DI | 22.73 |
| -DI | 15.49 |
| Chandelier Exit (Long, 3 ATRs ) | 1.83 |
| Chandelier Exit (Short, 3 ATRs ) | 2.23 |
| Upper Bollinger Band | 2.17 |
| Lower Bollinger Band | 1.87 |
| Percent B (%b) | 0.83 |
| BandWidth | 14.91 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.44 | ||||
| Resistance 3 (R3) | 2.45 | 2.35 | 2.38 | ||
| Resistance 2 (R2) | 2.35 | 2.27 | 2.35 | 2.37 | |
| Resistance 1 (R1) | 2.24 | 2.22 | 2.30 | 2.23 | 2.35 |
| Pivot Point | 2.14 | 2.14 | 2.17 | 2.14 | 2.14 |
| Support 1 (S1) | 2.03 | 2.06 | 2.08 | 2.01 | 1.89 |
| Support 2 (S2) | 1.93 | 2.01 | 1.93 | 1.87 | |
| Support 3 (S3) | 1.82 | 1.93 | 1.86 | ||
| Support 4 (S4) | 1.80 |
